Insulet (PODD) said Wednesday that a randomized controlled trial showed its Omnipod 5 automated insulin delivery system led to improved glycemic control, including an average 0.8% reduction in HbA1c levels after three months compared with multiple daily injections with a continuous glucose monitor.

Among those with a baseline HbA1c above 8.0%, the reduction was 1.0%. Omnipod 5 users also spent an average of 5.4 more hours per day with glucose levels in the target range of 70 to 180 mg/dL without an increase in hypoglycemia.

The study evaluated the direct transition from multiple daily injections to Omnipod 5 in adults and children with type 1 diabetes who were not meeting glycemic targets. Conducted across 19 sites in France, the UK, and Belgium, it included 188 participants aged 4 to 70 years.

No cases of severe hypoglycemia or diabetic ketoacidosis were reported, according to the company.